Table 1.

Drug target groupings. Drug targets with iLINCS signatures that are in use or under investigation for the treatment of COVID-19 were grouped together if they met a least two of the three following criteria: Canonical Mechanism of Action, referenced from the database DrugBank (https://www.drugbank.ca/); Anatomic Therapeutic Chemical classification, referenced from https://www.whocc.no/atc_ddd_index/.

Drug Cluster	Drug	Canonical Mechanism of Action	Anatomical Therapeutic Chemical First Level
1	Chloroquine, Hydroxychloroquine	Toll-like receptor antagonists	Antiparasitic Products, Insecticides and Repellants
2	Lopinavir, Ritonavir	Protease inhibitors	Anti-Infective for Systemic Use
3	Fedratinib, Ruxolinitib, Bariticinib	JAK inhibitors	Antineoplastic and Immunomodulating Agents
4	Azithromycin	Macrolide antibiotic	Anti-Infective for Systemic Use
5	Losartan	Angiotensin receptor blocker antagonist	Cardiovascular System